Needham analyst Serge Belanger maintained a Buy rating on KalVista Pharmaceuticals (KALV – Research Report) today and set a price target of $28.00. The company’s shares closed last Tuesday at $7.75, close to its 52-week low of $5.61.
According to TipRanks.com, Belanger has currently no stars on a ranking scale of 0-5 stars, with an average return of -7.9% and a 29.7% success rate. Belanger covers the Healthcare sector, focusing on stocks such as Amphastar Pharmaceuticals, Collegium Pharmaceutical, and Zynerba Pharmaceuticals.
Currently, the analyst consensus on KalVista Pharmaceuticals is a Moderate Buy with an average price target of $28.00.
Based on KalVista Pharmaceuticals’ latest earnings release for the quarter ending January 31, the company reported a quarterly revenue of $1.58 million and GAAP net loss of $9.29 million. In comparison, last year the company earned revenue of $3.89 million and had a GAAP net loss of $3.96 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
KalVista Pharmaceuticals, Inc. is a clinical stage pharmaceutical company, which engages in the discovery, development, and commercialization of small molecule protease inhibitors. Its product candidates are inhibitors of plasma kallikrein being developed for two indications: hereditary angioedema (HAE) and diabetic macular edema (DME). The company was founded by T. Andrew Crockett, Edward P. Feener, and Lloyd Paul Aiello and is headquartered in Cambridge, MA.